Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

Inclusion Criteria Patients may be eligible for this study if they: * Are at least 18 years old. * Are HIV-positive. * Are currently receiving one of the following anti-HIV drug combinations: Combivir plus abacavir, Combivir plus abacavir plus a protease inhibitor, or Combivir plus abacavir plus a non-nucleoside reverse transcriptase inhibitor (NNRTI). Patients must have been taking this drug combination for at least the past 16 weeks. This also must be the first anti-HIV drug combination the patient has received. * Have a viral load (level of HIV in the blood) less than or equal to 400 copies/ml. * Have CD4+ cell count greater than 200 cells/mm3. * Agree to use effective methods of birth control. Exclusion Criteria Patients will not be eligible for this study if they: * Have been diagnosed with AIDS. * Have a gastrointestinal disorder that makes it difficult for patients to absorb food or to take medications by mouth. * Have hepatitis. * Have a serious medical condition, such as diabetes, congestive heart failure, or other heart disease. * Are allergic to any of the study drugs. * Abuse alcohol or drugs. * Will not be available for the entire 24-week study period. * Are pregnant or breast-feeding. * Have taken or will need to take certain medications, including radiation therapy, chemotherapy, drugs that affect the immune system (such as interleukin), an HIV vaccine, foscarnet, and hydroxyurea. * Are enrolled in another experimental drug study.